GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Financing Rounds
-
1
GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) General Information
Description
Medication manufactured for the treatment of migraines. The tablets are effective in reducing symptoms of migraines, such as nausea and sensitivity to light or sound.
Contact Information
Corporate Office
- OT
- United States
Corporate Office
- OT
- United States
GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) FAQs
-
Where is GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) headquartered?
GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) is headquartered in OT.
-
What industry is GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) in?
GlaxoSmithKline (Treximet sumatriptan / naproxen sodium)’s primary industry is Drug Discovery.
-
Is GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) a private or public company?
GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) is a Private company.
-
What is the current valuation of GlaxoSmithKline (Treximet sumatriptan / naproxen sodium)?
The current valuation of GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) is .
-
What is GlaxoSmithKline (Treximet sumatriptan / naproxen sodium)’s current revenue?
The current revenue for GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) is .
-
Who are GlaxoSmithKline (Treximet sumatriptan / naproxen sodium)’s investors?
GSK has invested in GlaxoSmithKline (Treximet sumatriptan / naproxen sodium).
-
When was GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) acquired?
GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) was acquired on 20-Aug-2014.
-
Who acquired GlaxoSmithKline (Treximet sumatriptan / naproxen sodium)?
GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) was acquired by Pernix Therapeutical Holdings.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process